Institutional investors purchased a net $1.1 million shares of CYCC during the quarter ended September 2013 and now own 17.71% of the total shares outstanding. This is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 196.4 Thousand shares of Cyclacel Pharmaceuticals ...